Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2023-05-30 00:00:00 ET · period of report 2023-05-25 · accession 0001929354-23-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2023-05-30 | 2023-05-25+ | AVTX | Caissa Capital Management ltd. | 10% | P - Purchase | $2.80 | +2,671 | 1.39M | +0.2% | +$7,466 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-05-25 | P | A | 2,000 | $2.77 | 1,384,700 | I See Footnote (1) | — | — | (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. |
| 2 | Common | Common stock | 2023-05-30 | P | A | 671 | $2.87 | 1,385,371 | I See Footnote (1) | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.87, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. |